These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 12526824)

  • 21. Affinity and translocation relationships via hPEPT1 of H-X aa-Ser-OH dipeptides: evaluation of H-Phe-Ser-OH as a pro-moiety for ibuprofen and benzoic acid prodrugs.
    Omkvist DH; Trangbæk DJ; Mildon J; Paine JS; Brodin B; Begtrup M; Nielsen CU
    Eur J Pharm Biopharm; 2011 Feb; 77(2):327-31. PubMed ID: 21147219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport.
    Song X; Lorenzi PL; Landowski CP; Vig BS; Hilfinger JM; Amidon GL
    Mol Pharm; 2005; 2(2):157-67. PubMed ID: 15804190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and evaluation of tripeptidic promoieties targeting the intestinal peptide transporter hPEPT1.
    Thorn K; Andersen R; Christensen J; Jakobsen P; Nielsen CU; Steffansen B; Begtrup M
    ChemMedChem; 2007 Apr; 2(4):479-87. PubMed ID: 17407174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thiodipeptides targeting the intestinal oligopeptide transporter as a general approach to improving oral drug delivery.
    Foley DW; Pathak RB; Phillips TR; Wilson GL; Bailey PD; Pieri M; Senan A; Meredith D
    Eur J Med Chem; 2018 Aug; 156():180-189. PubMed ID: 30006163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir.
    Balimane PV; Tamai I; Guo A; Nakanishi T; Kitada H; Leibach FH; Tsuji A; Sinko PJ
    Biochem Biophys Res Commun; 1998 Sep; 250(2):246-51. PubMed ID: 9753615
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line.
    Guo A; Hu P; Balimane PV; Leibach FH; Sinko PJ
    J Pharmacol Exp Ther; 1999 Apr; 289(1):448-54. PubMed ID: 10087037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epidermal growth factor and insulin short-term increase hPepT1-mediated glycylsarcosine uptake in Caco-2 cells.
    Nielsen CU; Amstrup J; Nielsen R; Steffansen B; Frokjaer S; Brodin B
    Acta Physiol Scand; 2003 Jun; 178(2):139-48. PubMed ID: 12780388
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A peptide prodrug approach for improving bisphosphonate oral absorption.
    Ezra A; Hoffman A; Breuer E; Alferiev IS; Mönkkönen J; El Hanany-Rozen N; Weiss G; Stepensky D; Gati I; Cohen H; Törmälehto S; Amidon GL; Golomb G
    J Med Chem; 2000 Oct; 43(20):3641-52. PubMed ID: 11020278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes.
    Tao W; Zhao D; Sun M; Wang Z; Lin B; Bao Y; Li Y; He Z; Sun Y; Sun J
    Int J Pharm; 2018 Apr; 541(1-2):64-71. PubMed ID: 29471144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach.
    Gupta SV; Gupta D; Sun J; Dahan A; Tsume Y; Hilfinger J; Lee KD; Amidon GL
    Mol Pharm; 2011 Dec; 8(6):2358-67. PubMed ID: 21905667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Function and immunolocalization of overexpressed human intestinal H+/peptide cotransporter in adenovirus-transduced Caco-2 cells.
    Hsu CP; Walter E; Merkle HP; Rothen-Rutishauser B; Wunderli-Allenspach H; Hilfinger JM; Amidon GL
    AAPS PharmSci; 1999; 1(3):E12. PubMed ID: 11741208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro evaluation of N-methyl amide tripeptidomimetics as substrates for the human intestinal di-/tri-peptide transporter hPEPT1.
    Andersen R; Nielsen CU; Begtrup M; Jørgensen FS; Brodin B; Frokjaer S; Steffansen B
    Eur J Pharm Sci; 2006 Jul; 28(4):325-35. PubMed ID: 16713701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir.
    Gourdon B; Chemin C; Moreau A; Arnauld T; Baumy P; Cisternino S; Péan JM; Declèves X
    Int J Pharm; 2017 Aug; 529(1-2):357-370. PubMed ID: 28705621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of novel dipeptide ester prodrugs of acyclovir after oral administration: intestinal absorption and liver metabolism.
    Anand BS; Katragadda S; Mitra AK
    J Pharmacol Exp Ther; 2004 Nov; 311(2):659-67. PubMed ID: 15226381
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of intestinal dipeptide transport by the neuropeptide VIP is an anti-absorptive effect via the VPAC1 receptor in a human enterocyte-like cell line (Caco-2).
    Anderson CM; Mendoza ME; Kennedy DJ; Raldua D; Thwaites DT
    Br J Pharmacol; 2003 Feb; 138(4):564-73. PubMed ID: 12598410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
    Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
    Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug inhibition of Gly-Sar uptake and hPepT1 localization using hPepT1-GFP fusion protein.
    Sun D; Landowski CP; Chu X; Wallsten R; Komorowski TE; Fleisher D; Amidon GL
    AAPS PharmSci; 2001; 3(1):E2. PubMed ID: 11741253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A carrier-mediated prodrug approach to improve the oral absorption of antileukemic drug decitabine.
    Zhang Y; Sun J; Gao Y; Jin L; Xu Y; Lian H; Sun Y; Sun Y; Liu J; Fan R; Zhang T; He Z
    Mol Pharm; 2013 Aug; 10(8):3195-202. PubMed ID: 23822717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs.
    Han HK; Rhie JK; Oh DM; Saito G; Hsu CP; Stewart BH; Amidon GL
    J Pharm Sci; 1999 Mar; 88(3):347-50. PubMed ID: 10052994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conformational restrictions in ligand binding to the human intestinal di-/tripeptide transporter: implications for design of hPEPT1 targeted prodrugs.
    Våbenø J; Nielsen CU; Steffansen B; Lejon T; Sylte I; Jørgensen FS; Luthman K
    Bioorg Med Chem; 2005 Mar; 13(6):1977-88. PubMed ID: 15727852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.